Last updated: August 4, 2026
Heron Therapeutics sued Fresenius Kabi USA in the District of Delaware after Fresenius submitted an abbreviated new drug application seeking approval for a generic version of Zynrelef, Heron's extended-release bupivacaine and meloxicam product. The case, No. 1:22-cv-00985, ended without a reported merits ruling. The parties resolved the dispute through a confidential settlement, and the action was dismissed.
The settlement removed Fresenius Kabi from immediate generic-launch risk but did not eliminate the broader patent exposure surrounding Zynrelef. Heron's key commercial objective was to delay generic entry while preserving the Orange Book-listed patent estate, which extends beyond the product's FDA regulatory exclusivity period.
What drug and patents were involved in Heron Therapeutics v. Fresenius Kabi?
The litigation concerned Zynrelef, an extended-release local analgesic containing bupivacaine and meloxicam. FDA approved Zynrelef in May 2021 for use in adults to reduce postoperative pain for up to 72 hours after soft-tissue or small-to-medium open abdominal procedures.[1]
Heron asserted patents covering the composition and extended-release delivery system. Publicly associated Zynrelef patent families include the following patents:
| Patent |
General subject matter |
Listed patent term or estimated expiry |
| U.S. Patent No. 10,583,110 |
Extended-release bupivacaine and meloxicam compositions |
June 2037 |
| U.S. Patent No. 10,881,651 |
Local anesthetic and NSAID delivery formulations |
June 2037 |
| U.S. Patent No. 11,033,546 |
Extended-release analgesic compositions and use |
June 2037 |
| U.S. Patent No. 11,096,977 |
Zynrelef-related formulation and therapeutic-use claims |
June 2037 |
The precise asserted-claim set must be distinguished from the entire Orange Book portfolio. A branded drug company can list multiple patents while asserting only a subset against a particular ANDA applicant. Heron's complaint and subsequent docket filings control the patents and claims actually placed in controversy against Fresenius Kabi.
When was Heron v. Fresenius Kabi filed?
Heron filed the action in the U.S. District Court for the District of Delaware in 2022 after receiving Fresenius Kabi's Paragraph IV certification. The case was docketed as No. 1:22-cv-00985.
Under the Hatch-Waxman framework, an ANDA applicant may certify that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. A Paragraph IV notice generally gives the patent holder 45 days to sue. A timely infringement action can trigger a statutory stay of FDA approval for up to 30 months, subject to earlier termination or judicial resolution.[2]
Litigation timeline
| Date |
Event |
| May 2021 |
FDA approved Zynrelef for postoperative pain management.[1] |
| 2022 |
Fresenius Kabi submitted an ANDA with a Paragraph IV certification directed to Zynrelef-related patents. |
| 2022 |
Heron filed No. 1:22-cv-00985 in the District of Delaware. |
| 2023-2024 |
The parties negotiated a settlement rather than proceeding to a reported claim-construction or trial decision. |
| Following settlement |
The action was dismissed pursuant to the parties' settlement agreement. |
| Settlement effect |
Fresenius Kabi's generic launch was deferred under confidential commercial terms reported by Heron in its public filings. |
The public record does not establish a final judgment on infringement, validity, or enforceability. The case therefore provides limited precedent for evaluating the substantive strength of the asserted patents.
What was the legal basis of Heron's patent claims?
Heron's case arose from Fresenius Kabi's proposed generic product, not from an alleged commercial launch. The principal theories in a Hatch-Waxman case are:
- The proposed ANDA product would infringe composition or formulation claims.
- The proposed product would practice patented methods of administering the formulation for postoperative pain.
- Fresenius Kabi's Paragraph IV certifications created an artificial act of infringement under 35 U.S.C. § 271(e)(2).
The likely technical dispute centered on whether the generic formulation met claim limitations involving the combination of bupivacaine and meloxicam, the formulation's extended-release properties, and the delivery of the active ingredients at the surgical site.
What formulations are protected by the Zynrelef patents?
The Zynrelef patent estate is directed to more than the active ingredients considered separately. Its commercial protection is concentrated in the combination product and its delivery characteristics.
Relevant technical limitations may include:
- A local anesthetic, particularly bupivacaine.
- A nonsteroidal anti-inflammatory drug, particularly meloxicam.
- A controlled or extended-release matrix.
- Administration into or around a surgical site.
- Sustained analgesic delivery over approximately 72 hours.
- Specific concentration, particle, excipient, or release-profile limitations.
- Use of the formulation in postoperative pain treatment.
This type of portfolio can create meaningful ANDA barriers even when the individual active ingredients are old. A generic applicant may need to design around release kinetics, excipient composition, drug loading, administration method, or claim-specific concentration ranges.
What was the Paragraph IV challenge to Zynrelef?
Fresenius Kabi's Paragraph IV challenge indicated that it believed one or more listed patents were invalid, unenforceable, or not infringed by its proposed product. The certification allowed Fresenius Kabi to seek ANDA approval before expiration of the challenged patents, subject to the litigation stay and FDA regulatory requirements.
The filing of the lawsuit did not establish infringement. It created the statutory Hatch-Waxman case and gave Heron the opportunity to enforce its patents before a generic launch.
The case did not produce a reported opinion resolving:
- Claim construction.
- Anticipation or obviousness.
- Written description or enablement.
- Inequitable conduct.
- Infringement under the proposed ANDA formulation.
- The enforceability of the asserted patents.
The absence of a merits decision limits the value of the case for predicting how a court would treat the Zynrelef formulation claims against other ANDA applicants.
What was the settlement and when can Fresenius Kabi launch?
The settlement terms were confidential. Heron's public filings reported that Fresenius Kabi agreed to a deferred generic launch date for its Zynrelef product, subject to the agreement's conditions and exceptions.[3]
Publicly disclosed settlement information should be separated into two categories:
| Issue |
Public status |
| Monetary consideration |
Not publicly disclosed |
| Patent validity ruling |
None |
| Patent infringement ruling |
None |
| Settlement agreement |
Executed and confidential |
| Fresenius Kabi launch timing |
Deferred under reported settlement terms |
| FDA approval |
Not established by the civil docket alone |
| License or authorized-generic arrangement |
No public evidence of a broad commercial license |
A settlement launch date is not the same as a patent expiration date. It is a contractual entry restriction. Fresenius Kabi could potentially enter earlier if an exception in the agreement applies, if Heron materially breaches the agreement, or if relevant patents are invalidated or otherwise removed from the regulatory barrier.
What is the FDA regulatory and Orange Book status of Zynrelef?
Zynrelef received FDA approval through the NDA pathway. Its regulatory exclusivity and patent protection operate independently.
FDA exclusivity
Zynrelef was approved as a combination product containing previously known active ingredients. Its commercial protection therefore depends heavily on patents because regulatory exclusivity for the combination does not extend to the full patent term.
FDA approval occurred in May 2021. The product received a period of new-clinical-investigation exclusivity associated with the approval, but that exclusivity did not extend into the 2030s. The relevant FDA exclusivity period has expired or is no longer the principal barrier to ANDA approval.
Orange Book listings
The Orange Book identifies patents and regulatory exclusivity associated with approved drug products. Listed Zynrelef patents can delay ANDA approval or create litigation exposure, but an Orange Book listing does not prove that every listed patent will survive invalidity review or cover every generic design.[4]
The practical distinction is:
- FDA exclusivity controls when FDA may approve a competing application.
- Orange Book patents identify potential patent barriers.
- Hatch-Waxman litigation determines whether a particular ANDA product can lawfully launch before patent expiry.
- Settlement agreements can impose a later contractual launch date than the minimum date required by the patents.
How strong is Heron's Zynrelef patent estate?
Heron's patent estate is commercially meaningful but not immune from challenge.
Strengths
The portfolio has several characteristics favorable to enforcement:
- It protects a combination product rather than only an individual active ingredient.
- It includes formulation and delivery concepts that may be difficult to copy without reproducing claim limitations.
- Continuation patents can provide layered claim scope.
- The patents have long remaining terms relative to Zynrelef's 2021 approval.
- The product's sustained-release performance can support technical distinctions from conventional bupivacaine products.
Vulnerabilities
The principal risks include:
- Obviousness challenges based on known bupivacaine, meloxicam, depot, and extended-release technologies.
- Written-description and enablement challenges if broad claims exceed the disclosed formulation data.
- Noninfringement arguments based on release profile, excipients, concentration, or manufacturing differences.
- Patent-term and Orange Book listing disputes.
- The possibility that a generic applicant develops a noninfringing formulation rather than reproducing the branded product's exact formulation.
Because Fresenius Kabi settled before a merits decision, the public docket does not validate the patents. The settlement demonstrates negotiated commercial value, not judicial confirmation of patent validity.
Which companies are challenging Zynrelef patents?
Fresenius Kabi was one of the ANDA applicants involved in Zynrelef patent enforcement. Heron has also disclosed patent litigation or patent-related disputes involving other generic applicants over time. The competitive risk should be analyzed applicant by applicant because each ANDA may use different certifications, formulation designs, and settlement terms.
A settlement with one applicant does not automatically bind other applicants. Each defendant can raise separate invalidity and noninfringement defenses, and each may have a distinct agreed launch date.
Are biosimilars a risk to Zynrelef?
No. Zynrelef is a small-molecule combination drug, not a biologic. Biosimilar litigation under the Biologics Price Competition and Innovation Act is not the relevant pathway.
The applicable competitive threat is an ANDA-based generic. Generic applicants may challenge Orange Book patents through Paragraph IV certifications or wait for patent and regulatory barriers to expire.
What generic launch scenarios exist for Zynrelef?
The main scenarios are:
| Scenario |
Commercial consequence |
| Settlement-controlled launch |
Fresenius Kabi launches on the agreed date, subject to settlement conditions. |
| Earlier entry after patent defeat |
A generic launches if a court invalidates or finds noninfringement of blocking patents. |
| Design-around entry |
A competitor develops a formulation outside the asserted claims. |
| At-risk launch |
A generic launches before final patent resolution, accepting potential damages and injunction exposure. |
| Post-expiry entry |
Generic competition begins after the relevant patents and regulatory barriers no longer block approval. |
For Heron, the most material near-term risk is not FDA exclusivity. It is the number, timing, and technical scope of ANDA challenges against the remaining Zynrelef patent estate.
What patent litigation affects Heron's Zynrelef revenue?
Zynrelef revenue is exposed to generic entry because hospital and ambulatory-surgery customers can substitute lower-priced products if a therapeutically acceptable generic becomes available.
The commercial impact depends on:
- The number of approved generic products.
- Whether a generic reproduces Zynrelef's 72-hour delivery profile.
- Payer and hospital formulary adoption.
- Generic launch timing under each settlement.
- Heron's ability to maintain pricing and clinical differentiation.
- The survival of formulation and method-of-use patents.
A single delayed generic launch reduces immediate pressure but does not establish long-term exclusivity. Revenue forecasts should use applicant-specific launch dates rather than the latest patent expiration date alone.
Key Takeaways
- Heron Therapeutics v. Fresenius Kabi USA, No. 1:22-cv-00985, was a Hatch-Waxman patent case involving a proposed generic version of Zynrelef.
- Heron asserted patents directed to the bupivacaine-meloxicam combination, extended-release formulation, and related therapeutic uses.
- The case ended through a confidential settlement and dismissal, without a reported ruling on validity, infringement, or enforceability.
- Fresenius Kabi's entry was deferred under the settlement terms reported in Heron's public filings.
- Zynrelef's principal long-term protection comes from patents, not FDA exclusivity.
- The product is subject to generic, not biosimilar, competition.
- The settlement has limited precedential value because it did not test the asserted claims in court.
FAQs About Heron Therapeutics v. Fresenius Kabi
Did Heron win the Zynrelef patent case?
No merits victory was reported. The parties settled and the case was dismissed, so the docket does not establish that Heron's patents were valid or infringed.
Is Fresenius Kabi allowed to sell generic Zynrelef?
Fresenius Kabi may be able to launch under the terms of its settlement with Heron and after satisfying FDA approval requirements. The settlement deferred entry but did not itself constitute FDA approval.
What is the latest Zynrelef patent expiration date?
Publicly associated Zynrelef patents extend into approximately June 2037, although the effective barrier depends on patent scope, terminal disclaimers, regulatory listing, and any applicable term adjustments.
Can another generic company launch before Fresenius Kabi?
Yes, in principle. A separate ANDA applicant is governed by its own patents, certifications, litigation, and settlement terms. Fresenius Kabi's agreement does not automatically control competitors.
Does the case create a precedent for Zynrelef patent validity?
No. Because the case ended without a reported merits decision, it does not provide binding or persuasive adjudication on the validity or infringement of Heron's Zynrelef patents.
References
-
U.S. Food and Drug Administration. (2021). Zynrelef approval letter and prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and ANDA patent certifications. FDA.
-
Heron Therapeutics, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1365916
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
